Assessment of the immune deficit in leprosy patients and the effect of recombinant IL-2 in vitro.
Although the mechanism of immunologic unresponsiveness in lepromatous leprosy remains unknown, it has been shown that interleukin-2 (IL-2) production is defective in these patients. Peripheral blood mononuclear cells (PBMC) were isolated from treated (less than 16 months) and untreated leprosy patients as well as household contacts; age, sex, ethnically matched control subjects; and laboratory staff. PBMC were cultured for 6 days with sonicated Mycobacterium leprae (1-10 micrograms/ml), Dharmendra lepromin (1:10), or phenolic glycolipid-I (PGL-I) (0.05-5.0 micrograms/ml) in medium supplemented with various concentrations of recombinant IL-2 (rIL-2) or cultured for 3 days with one of the three mycobacterial antigens in the presence of concanavalin A (ConA). TT/BT patients and household control subjects had a robust response to M. leprae and lepromin, but were unresponsive to PGL-I delivered in liposomes. PBMC from LL patients did not respond to any of the three antigen preparations. rIL-2 induced proliferation of PBMC both in leprosy patients and control subjects regardless of the presence or absence of the three leprosy antigen preparations. This antigen nonspecific augmentation of proliferation by the wide range of doses of rIL-2 employed makes difficult the interpretation of the enhanced thymidine incorporation noted when rIL-2 is added in the presence of antigen to cultures of lymphocytes from LL patients. Our studies are at variance with reports that leprosy antigens, specifically PGL-I, induce immunological suppression, in that mycobacterial antigens did not cause significant suppression of the ConA-induced proliferations of PBMC from patients.
Locniskar
M
M
McEniry
D W
DW
Mudd
D W
DW
Rose
P
P
Lucas
D C
DC
Larrick
J
J
McAdam
K P
KP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000942:Antigens, Bacterial; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D005260:Female; D006017:Glycolipids / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007376:Interleukin-2 / Q000276:immunology*; D007916:Lepromin / Q000276:immunology; D007918:Leprosy / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000276:immunology; D011994:Recombinant Proteins
D000942:Antigens, Bacterial; D006017:Glycolipids; D007376:Interleukin-2; D011994:Recombinant Proteins; C045169:phenolic glycolipid I, Mycobacterium leprae; D007916:Lepromin; D003208:Concanavalin A